Probing the Inhibitor versus Chaperone Properties of sp2-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease

A series of sp2-iminosugar glycomimetics differing in the reducing or nonreducing character, the configurational pattern (d-gluco or l-ido), the architecture of the glycone skeleton, and the nature of the nonglycone substituent has been synthesized and assayed for their inhibition properties towards commercial glycosidases. On the basis of their affinity and selectivity towards GH1 β-glucosidases, reducing and nonreducing bicyclic derivatives having a hydroxylation profile of structural complementarity with d-glucose and incorporating an N′-octyl-isourea or -isothiourea segment were selected for further evaluation of their inhibitory/chaperoning potential against human glucocerebrosidase (GCase). The 1-deoxynojirimycin (DNJ)-related nonreducing conjugates behaved as stronger GCase inhibitors than the reducing counterparts and exhibited potent chaperoning capabilities in Gaucher fibroblasts hosting the neuronopathic G188S/G183W mutation, the isothiourea derivative being indeed one of the most efficient chaperone candidates reported up to date (70% activity enhancement at 20 pM). At their optimal concentration, the four selected compounds promoted mutant GCase activity enhancements over 3-fold; yet, the inhibitor/chaperoning balance became unfavorable at much lower concentration for nonreducing as compared to reducing derivatives.

[1]  A. Aliev,et al.  Noncovalent Interactions of π Systems with Sulfur: The Atomic Chameleon of Molecular Recognition. , 2018, Angewandte Chemie.

[2]  P. Andrade,et al.  Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones , 2018, Chemical science.

[3]  D. Goldstein,et al.  Drug development in the era of precision medicine , 2017, Nature Reviews Drug Discovery.

[4]  H. Ouadid‐Ahidouch,et al.  sp2‐Iminosugar α‐glucosidase inhibitor 1‐C‐octyl‐2‐oxa‐3‐oxocastanospermine specifically affected breast cancer cell migration through Stim1, β1‐integrin, and FAK signaling pathways , 2017, Journal of cellular physiology.

[5]  R. Pieters,et al.  Orthoester functionalized N-guanidino derivatives of 1,5-dideoxy-1,5-imino-d-xylitol as pH-responsive inhibitors of β-glucocerebrosidase. , 2017, MedChemComm.

[6]  M. O. Mitchell.  Discovering protein−ligand chalcogen bonding in the protein data bank using endocyclic sulfur-containing heterocycles as ligand search subsets , 2017, Journal of Molecular Modeling.

[7]  C. Ortiz Mellet,et al.  Multivalency as an action principle in multimodal lectin recognition and glycosidase inhibition: a paradigm shift driven by carbon-based glyconanomaterials. , 2017, Journal of materials chemistry. B.

[8]  H. Williams,et al.  Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment , 2017, Journal of Medical Genetics.

[9]  Andrew H. Chiang,et al.  Protein Misfolding Diseases. , 2017, Annual review of biochemistry.

[10]  C. Ortiz Mellet,et al.  The Impact of Heteromultivalency in Lectin Recognition and Glycosidase Inhibition: An Integrated Mechanistic Study. , 2017, Chemistry.

[11]  R. Pieters,et al.  N‐Guanidino Derivatives of 1,5‐Dideoxy‐1,5‐imino‐d‐xylitol are Potent, Selective, and Stable Inhibitors of β‐Glucocerebrosidase , 2017, ChemMedChem.

[12]  J. Frydman,et al.  Protein misfolding in neurodegenerative diseases: implications and strategies , 2017, Translational Neurodegeneration.

[13]  K. Higaki,et al.  Fluorinated Chaperone-β-Cyclodextrin Formulations for β-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease. , 2017, Journal of medicinal chemistry.

[14]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[15]  D. Lockhart,et al.  Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study , 2016, Journal of Medical Genetics.

[16]  K. Higaki,et al.  Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts. , 2016, European journal of medicinal chemistry.

[17]  K. Higaki,et al.  Efficient stereoselective synthesis of 2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc) and sp(2)-iminosugar conjugates: Novel hexosaminidase inhibitors with discrimination capabilities between the mature and precursor forms of the enzyme. , 2016, European journal of medicinal chemistry.

[18]  D. Lockhart,et al.  The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat , 2016, Genetics in Medicine.

[19]  R. Pieters,et al.  Bicyclic isoureas derived from 1-deoxynojirimycin are potent inhibitors of β-glucocerebrosidase. , 2016, Organic & biomolecular chemistry.

[20]  M. Lutz,et al.  Exploring the Chemistry of Bicyclic Isoxazolidines for the Multicomponent Synthesis of Glycomimetic Building Blocks. , 2016, The Journal of organic chemistry.

[21]  C. Ortiz Mellet,et al.  Correction to "Generalized Anomeric Effect in gem-Diamines: Stereoselective Synthesis of α-N-Linked Disaccharide Mimics". , 2016, Organic Letters.

[22]  Á. Valverde,et al.  Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. , 2016, Biochimica et biophysica acta.

[23]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[24]  C. Ortiz Mellet,et al.  Potent Glycosidase Inhibition with Heterovalent Fullerenes: Unveiling the Binding Modes Triggering Multivalent Inhibition. , 2016, Chemistry.

[25]  G. Jiménez‐Osés,et al.  Tn Antigen Mimics Based on sp(2)-Iminosugars with Affinity for an anti-MUC1 Antibody. , 2016, Organic letters.

[26]  A. Markham.  Migalastat: First Global Approval , 2016, Drugs.

[27]  C. Ortiz Mellet,et al.  Influence of the configurational pattern of sp(2)-iminosugar pseudo N-, S-, O- and C-glycosides on their glycoside inhibitory and antitumor properties. , 2016, Carbohydrate research.

[28]  S. Withers,et al.  The Staudinger/aza-Wittig/Grignard reaction as key step for the concise synthesis of 1-C-Alkyl-iminoalditol glycomimetics. , 2016, Carbohydrate research.

[29]  E. Sánchez-Fernández,et al.  Glycomimetic-Based Pharmacological Chaperones for Lysosomal Storage Disorders: Lessons from Gaucher, GM1-Gangliosidosis and Fabry Diseases , 2016 .

[30]  N. Dokholyan,et al.  Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases. , 2016, ACS chemical biology.

[31]  J. G. García Fernández,et al.  Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. , 2016, Chemical communications.

[32]  Yoshiyuki Suzuki,et al.  pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases. , 2015, Angewandte Chemie.

[33]  Salvador Ventura,et al.  Protein misfolding diseases , 2015, Future science OA.

[34]  G. Andria,et al.  Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  C. Ortiz Mellet,et al.  Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease , 2015, Scientific Reports.

[36]  M. Bergeron-Brlek,et al.  Direct synthesis of imino-C-nucleoside analogues and other biologically active iminosugars , 2015, Nature Communications.

[37]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[38]  D. Vocadlo,et al.  Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity. , 2015, Journal of the American Chemical Society.

[39]  E. Álvarez,et al.  Synthesis of multibranched australine derivatives from reducing castanospermine analogues through the Amadori rearrangement of gem-diamine intermediates: selective inhibitors of β-glucosidase. , 2014, The Journal of organic chemistry.

[40]  O. Martin,et al.  Stereoselective Synthesis of 1-C-Alkyl Iminogalactitol Derivatives, Potential Chaperones for Galactosidase-Linked LSDs: A Real Challenge. , 2014 .

[41]  Yoshiyuki Suzuki,et al.  Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants. , 2014, ACS chemical biology.

[42]  Toshiyuki Shimizu,et al.  Structural Basis of Pharmacological Chaperoning for Human β-Galactosidase* , 2014, The Journal of Biological Chemistry.

[43]  P. Compain.  Searching for Glycomimetics That Target Protein Misfolding in Rare Diseases: Successes, Failures, and Unexpected Progress Made in Organic Synthesis , 2014, Synlett.

[44]  Yoshiyuki Suzuki,et al.  Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier. , 2014, Organic & biomolecular chemistry.

[45]  C. Ortiz Mellet,et al.  Fullerene-sp2-iminosugar balls as multimodal ligands for lectins and glycosidases: a mechanistic hypothesis for the inhibitory multivalent effect. , 2013, Chemistry.

[46]  C. O. Mellet,et al.  N‐Thiocarbonyl Iminosugars: Synthesis and Evaluation of Castanospermine Analogues Bearing Oxazole‐2(3H)‐thione Moieties , 2013 .

[47]  M. Górecki,et al.  Glucosylceramide Mimics: Highly Potent GCase Inhibitors and Selective Pharmacological Chaperones for Mutations Associated with Types 1 and 2 Gaucher Disease , 2013, ChemMedChem.

[48]  J. M. Fernandez,et al.  New Castanospermine Glycoside Analogues Inhibit Breast Cancer Cell Proliferation and Induce Apoptosis without Affecting Normal Cells , 2013, PloS one.

[49]  F. Sánchez-Jiménez,et al.  Bicyclic Derivatives of L‐Idonojirimycin as Pharmacological Chaperones for Neuronopathic Forms of Gaucher Disease , 2013, Chembiochem : a European journal of chemical biology.

[50]  Kei Yura,et al.  A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  J. I. Izpisúa Belmonte,et al.  Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. , 2013, Human molecular genetics.

[52]  H. Lester,et al.  Functionally important aromatic-aromatic and sulfur-π interactions in the D2 dopamine receptor. , 2012, Journal of the American Chemical Society.

[53]  J. Angulo,et al.  sp2-Iminosugar O-, S-, and N-glycosides as conformational mimics of α-linked disaccharides; implications for glycosidase inhibition. , 2012, Chemistry.

[54]  Y. Sakakibara,et al.  Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. , 2012, Chemical communications.

[55]  T. Butters,et al.  Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease. , 2012, Journal of medicinal chemistry.

[56]  C. Ortiz Mellet,et al.  Synthesis and glycosidase inhibitory activity of isourea-type bicyclic sp2-iminosugars related to galactonojirimycin and allonojirimycin , 2012 .

[57]  G. Fleet,et al.  Iminosugars as therapeutic agents: recent advances and promising trends. , 2011, Future medicinal chemistry.

[58]  A. Llebaria,et al.  Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase. , 2011, Organic & biomolecular chemistry.

[59]  J. Sussman,et al.  Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues. , 2011, Organic & biomolecular chemistry.

[60]  J. M. Benito,et al.  Pharmacological chaperone therapy for Gaucher disease: a patent review , 2011, Expert opinion on therapeutic patents.

[61]  T. Butters,et al.  Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells. , 2011, Journal of the American Chemical Society.

[62]  D. H. Williams,et al.  Iminosugars past, present and future: medicines for tomorrow. , 2011, Drug discovery today.

[63]  H. Ouadid‐Ahidouch,et al.  Synthesis of N-, S-, and C-Glycoside Castanospermine Analogues with Selective Neutral α-Glucosidase Inhibitory Activity as Antitumor Agents. , 2010 .

[64]  Yoshiyuki Suzuki,et al.  A Fluorescent sp2‐Iminosugar With Pharmacological Chaperone Activity for Gaucher Disease: Synthesis and Intracellular Distribution Studies , 2010, Chembiochem : a European journal of chemical biology.

[65]  T. Wrodnigg,et al.  Fluorescent-tagged sp2-iminosugars with potent β-glucosidase inhibitory activity. , 2010, Bioorganic & medicinal chemistry.

[66]  C. Ortiz Mellet,et al.  Synthesis of N-, S-, and C-glycoside castanospermine analogues with selective neutral alpha-glucosidase inhibitory activity as antitumour agents. , 2010, Chemical communications.

[67]  H. Overkleeft,et al.  Synthesis and Evaluation of Lipophilic Aza‐C‐glycosides as Inhibitors of Glucosylceramide Metabolism , 2010 .

[68]  Yoshiyuki Suzuki,et al.  Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N‐(n‐nonyl)Deoxynojirimycin , 2009, Chembiochem : a European journal of chemical biology.

[69]  Beat Ernst,et al.  From carbohydrate leads to glycomimetic drugs , 2009, Nature Reviews Drug Discovery.

[70]  C. Ortiz Mellet,et al.  Generalized anomeric effect in gem-diamines: stereoselective synthesis of alpha-N-linked disaccharide mimics. , 2009, Organic letters.

[71]  J. Turkenburg,et al.  Glycosidase inhibition by ring-modified castanospermine analogues: tackling enzyme selectivity by inhibitor tailoring. , 2009, Organic & biomolecular chemistry.

[72]  J. Sussman,et al.  6‐Amino‐6‐deoxy‐5,6‐di‐N‐(N′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase , 2009, Chembiochem : a European journal of chemical biology.

[73]  J. G. García Fernández,et al.  Synthesis of thiohydantoin-castanospermine glycomimetics as glycosidase inhibitors. , 2009, The Journal of organic chemistry.

[74]  G. Davies,et al.  Molecular Basis for β‐Glucosidase Inhibition by Ring‐Modified Calystegine Analogues , 2008, Chembiochem : a European journal of chemical biology.

[75]  Brandi L. Cantarel,et al.  The Carbohydrate-Active EnZymes database (CAZy): an expert resource for Glycogenomics , 2008, Nucleic Acids Res..

[76]  C. Ortiz Mellet,et al.  Synthesis and evaluation of sulfamide-type indolizidines as glycosidase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[77]  J. G. García Fernández,et al.  Synthesis and biological evaluation of guanidine-type iminosugars. , 2008, The Journal of organic chemistry.

[78]  C. O. Mellet,et al.  Synthesis and biological evaluation of 6-oxa-nor-tropane glycomimetics as glycosidase inhibitors , 2007 .

[79]  C. Ortiz Mellet,et al.  Synthesis and Comparative Glycosidase Inhibitory Properties of Reducing Castanospermine Analogues , 2005 .

[80]  J. G. García Fernández,et al.  Pseudoamide-type pyrrolidine and pyrrolizidine glycomimetics and their inhibitory activities against glycosidases. , 2004, The Journal of organic chemistry.

[81]  M. I. García-Moreno,et al.  Synthesis of Calystegine B2, B3, and B4 Analogues: Mapping the Structure‐Glycosidase Inhibitory Activity Relationships in the 1‐Deoxy‐6‐oxacalystegine Series , 2004 .

[82]  C. Ortiz Mellet,et al.  Synthesis and evaluation of isourea-type glycomimetics related to the indolizidine and trehazolin glycosidase inhibitor families. , 2003, The Journal of organic chemistry.

[83]  M. I. García-Moreno,et al.  Synthesis of (1S, 2S, 3R, 8S, 8Ar)-1,2,3,8-tetrahydroxy-6-oxa-5-thioxoindolizidine: A stable reducing swainsonine analog with controlled anomeric configuration , 2003 .

[84]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Ortiz Mellet,et al.  Castanospermine-trehazolin hybrids: a new family of glycomimetics with tuneable glycosidase inhibitory properties. , 2002, Chemical communications.

[86]  J. M. Benito,et al.  Synthesis and evaluation of calystegine B2 analogues as glycosidase inhibitors. , 2001, The Journal of organic chemistry.

[87]  R. Campbell,et al.  Miglitol: Assessment of its Role in the Treatment of Patients with Diabetes Mellitus , 2000, The Annals of pharmacotherapy.

[88]  F. Cañada,et al.  Generalized anomeric effect in action: synthesis and evaluation of stable reducing indolizidine glycomimetics as glycosidase inhibitors. , 2000, The Journal of organic chemistry.

[89]  M. I. García-Moreno,et al.  Polyhydroxylated N-(thio)carbamoyl piperidines: nojirimycin-type glycomimetics with controlled anomeric configuration , 1999 .

[90]  J. M. Benito,et al.  SYNTHESIS OF CALYSTEGINE B2 ANALOGS BY TANDEM TAUTOMERIZATION-INTRAMOLECULAR GLYCOSYLATION OF THIOUREIDOSUGARS , 1998 .

[91]  F. Cañada,et al.  N-Thiocarbonyl Azasugars: A New Family of Carbohydrate Mimics with Controlled Anomeric Configuration. , 1998 .

[92]  Á. Valverde,et al.  The sp2-iminosugar glycolipid 1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin (DSO2-ONJ) as selective anti-inflammatory agent by modulation of hemeoxygenase-1 in Bv.2 microglial cells and retinal explants. , 2018, Food and Chemical Toxicology.

[93]  M. Govindarajan.  Amphiphilic glycoconjugates as potential anti-cancer chemotherapeutics. , 2018, European journal of medicinal chemistry.

[94]  G. Horne.  Iminosugars: Therapeutic Applications and Synthetic Considerations , 2014 .

[95]  D. Lockhart,et al.  The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  F. Cañada,et al.  N-THIOCARBONYL AZASUGARS : A NEW FAMILY OF CARBOHYDRATE MIMICS WITH CONTROLLED ANOMERIC CONFIGURATION , 1997 .